Goldman Sachs
CLSD

Goldman Sachs’s Clearside Biomedical CLSD Stock Holding History

Goldman Sachs’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,287
Closed -$22K – 6007
2022
Q3 		$22K Sell
1,287
-121
-9% -$2.65K ﹤0.01% 5915
2022
Q2 		$31K Sell
1,408
-1,015
-42% -$24.6K ﹤0.01% 6117
2022
Q1 		$84K Sell
2,423
-2,874
-54% -$86K ﹤0.01% 6156
2021
Q4 		$219K Buy
5,297
+2,176
+70% +$141K ﹤0.01% 5848
2021
Q3 		$281K Buy
3,121
+2,003
+179% +$177K ﹤0.01% 5533
2021
Q2 		$82K Buy
+1,118
New +$52K ﹤0.01% 5987
2019
Q3 		– Sell
-8,139
Closed -$119K – 5183
2019
Q2 		$119K Buy
+8,139
New +$145K ﹤0.01% 4895
2019
Q1 		– Sell
-1,576
Closed -$25K – 5172
2018
Q4 		$25K Sell
1,576
-2,441
-61% -$115K ﹤0.01% 5137
2018
Q3 		$371K Buy
4,017
+1,745
+77% +$207K ﹤0.01% 4583
2018
Q2 		$365K Sell
2,272
-875
-28% -$148K ﹤0.01% 4685
2018
Q1 		$507K Sell
3,147
-12
-0.4% -$1.46K ﹤0.01% 4482
2017
Q4 		$332K Buy
3,159
+714
+29% +$76.7K ﹤0.01% 5117
2017
Q3 		$321K Buy
2,445
+119
+5% +$14.5K ﹤0.01% 5419
2017
Q2 		$318K Sell
2,326
-597
-20% -$71.7K ﹤0.01% 5457
2017
Q1 		$348K Buy
2,923
+731
+33% +$86.3K ﹤0.01% 5331
2016
Q4 		$294K Buy
+2,192
New +$550K ﹤0.01% 5500
2016
Q3 		– Sell
-2,400
Closed -$252K – 7031
2016
Q2 		$252K Buy
+2,400
New +$252K ﹤0.01% 5493

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs's CLSD Position: Q4 2022 in Review

Goldman Sachs sold out of Clearside Biomedical (CLSD) in Q4 2022, closing a stake of 1,287 shares — an estimated $22K sold.

Goldman Sachs first reported a position in CLSD in Q2 2016 and held it in 17 quarters. The position peaked at $507K in Q1 2018. 53 funds tracked by Wall St. Rank hold CLSD as of Q4 2022.

  • Goldman Sachs reported no remaining Clearside Biomedical position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,287 Clearside Biomedical shares in Q4 2022, an estimated $22K.
  • Goldman Sachs first reported a position in Clearside Biomedical in Q2 2016 and held it in 17 quarters.
  • Goldman Sachs's Clearside Biomedical position peaked at $507K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.